‘We’re the outlier of developed healthcare economies’ in Canada
Canada does not have a program to entice pharmaceutical companies to develop and market drugs for rare disorders here. So companies are going elsewhere.
Gordon McCauley is set to start the final study on his pharmaceutical company Allon Therapeutics Inc.'s drug to fight a rare brain disorder, before seeking regulatory approval. But although the company is based in Vancouver, B.C., he will seek to get his drug approved first in the United States.
SPONSORED CONTENT
Get Tuesdays: Innovation & Industry Newsletter
The policies, decisions, and people working on investment and regulation in the industry and innovation realm.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
